Zimmer Biomet Holdings Inc (ZBH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Zimmer Biomet Holdings Inc (ZBH) reports robust Q4 performance with nearly 5% constant currency revenue growth and outlines strategic plans for future innovation and market expansion.
RBC Capital Sticks to Its Buy Rating for Zimmer Biomet Holdings (ZBH)
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report) yesterday and set a price
Zimmer Biomet Holdings, Inc. (ZBH) Q4 2024 Earnings Call Transcript
Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, February 06,
Zimmer Biomet forecasts 2025 profit below estimates
Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar.
Wells Fargo Keeps Their Hold Rating on Zimmer Biomet Holdings (ZBH)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report),
Zimmer Biomet (ZBH) Surpasses Q4 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago. These figures are adjusted for non-recurring items.
Zimmer Biomet reports Q4 earnings beat, revenue up 4.3%
WARSAW, Ind. - Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported fourth quarter earnings that slightly exceeded analyst expectations, with revenue growth driven by strong performance across its product portfolio.
Zimmer Biomet Holdings Inc. Q4 Profit Decreases, But Beats Estimates
Zimmer Biomet Holdings Inc. (ZBH) announced a profit for fourth quarter that decreased from the same period last year but beat the
Zimmer Biomet projects 3%-5% revenue growth for 2025 with over 50 product launches in 36 months
Q4 2024 Management View CEO Ivan Tornos highlighted that Zimmer Biomet achieved nearly 5% constant currency sales growth in Q4 2024, marking the 12th consecutive quarter of mid-single-digit or better growth.
Earnings call transcript: Zimmer Biomet Q4 2024 sees strong sales growth
Inc. reported robust financial results for the fourth quarter of 2024, surpassing analysts' expectations with an earnings per share (EPS) of $2.31, slightly above the forecast of $2.30. The company's revenue reached $2.
ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket
Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in ...
Zimmer Biomet: Adding To The Growth Profile
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 ...
Why Is Zimmer Biomet Stock Trading Lower On Thursday?
Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the ...
Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors
Shares of Zimmer Biomet Holdings Inc. ZBH slipped 5.14% to $102.69 Thursday, on what proved to be an all-around mixed trading ...